Mr Norman J Blears

Norman J Blears


Healthcare & Life Sciences

Securities class actions in the life sciences sector: key trends
USA | 29 June 2016

Recent securities class actions brought against life sciences companies offer valuable insight into developments in this field. At the most basic level, the cases analysed share a common feature. In each, a life sciences company suffered a setback that, when publicised, was followed first by a stock price decline and then by litigation initiated by shareholders seeking to recover investment losses.